Stanford University
Showing 6,461-6,470 of 7,777 Results
-
Julius Smith
Professor of Music, Emeritus
BioSmith is a professor emeritus of music and (by courtesy) electrical engineering (Information Systems Lab) based at the Center for Computer Research in Music and Acoustics (CCRMA). Teaching and research pertain to music and audio applications of signal processing. Former software engineer at NeXT Computer, Inc., responsible for signal processing software pertaining to music and audio. For more, see https://ccrma.stanford.edu/~jos/.
-
Mark Smith
Senior Research Scientist, Sarafan ChEM-H
BioDr. Mark Smith is Director of the Medicinal Chemistry within the Sarafan ChEM-H Institute Nucleus and Co-Director of the Small Molecule Portfolio in Stanford's Innovative Medicines Accelerator (IMA). In addition, Dr. Smith is Director of the Sarafan ChEM-H Undergraduate Entrepreneurship Program. Prior to Stanford, Dr. Smith was a Senior Scientist at Roche Pharmaceuticals where his research focused on the discovery of small molecule inhibitors for HIV reverse transcriptase, HCV polymerase and NS5A, influenza endonuclease and cap polymerase. Dr. Smith also led Roche's nucleoside chemistry efforts in the virology therapeutic area.
-
Matthew Smith
Professor of German Studies and of Theater and Performance Studies
BioMatthew Wilson Smith’s interests include modern theatre and relations between science, technology, and the arts. His book The Nervous Stage: 19th-century Neuroscience and the Birth of Modern Theatre (Oxford, 2017) explores historical intersections between theatre and neurology and traces the construction of a “neural subject” over the course of the nineteenth century. It was a finalist for the George Freedley Memorial Award of the Theater Library Association. His previous book, The Total Work of Art: From Bayreuth to Cyberspace (Routledge, 2007), presents a history and theory of attempts to unify the arts; the book places such diverse figures as Wagner, Moholy-Nagy, Brecht, Riefenstahl, Disney, Warhol, and contemporary cyber-artists within a coherent genealogy of multimedia performance. He is the editor of Georg Büchner: The Major Works, which appeared as a Norton Critical Edition in 2011, and the co-editor of Modernism and Opera (Johns Hopkins, 2016), which was shortlisted for an MSA Book Prize. His essays on theater, opera, film, and virtual reality have appeared widely, and his work as a playwright has appeared at the Eugene O’Neill Musical Theater Conference, Richard Foreman’s Ontological-Hysteric Theater, and other stages. He previously held professorships at Cornell University and Boston University as well as visiting positions at Columbia University and Johannes Gutenberg-Universität (Mainz).
-
Melody Smith, MD, MS
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Smith is a board-certified, fellowship-trained medical oncologist and hematologist. She is an Assistant Professor in the Department of Medicine within the Division of Blood & Marrow Transplantation and Cellular Therapy.
She is also a physician-scientist who conducts extensive research. As a medical student, she completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program. Subsequently, after her clinical fellowship, she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. Her lab's research focuses on studying the biology of chimeric antigen receptor (CAR) T cells to improve the therapy's efficacy and safety (1) by examining donor (Nature Medicine, 2017) and off-the-shelf CAR T cells in mouse models and (2) by investigating how the intestinal microbiome affects CAR T cell response (Nature Medicine, 2022).
Dr. Smith presents her research findings at regional, national, and international conferences. Additionally, she has co-authored articles on topics in cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has been published in journals such as Nature, Nature Immunology, Nature Medicine, Blood, and Transplantation and Cellular Therapy. She serves as a peer reviewer for publications like NEJM Evidence, Science Advances, Blood, Cancer Cell, and Molecular Therapy. She has also contributed chapters to books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.
She has received numerous honors; the American Society of Hematology, the American Society for Clinical Investigation, the Society for Immunotherapy of Cancer, the European Society for Blood and Marrow Transplantation, and several other professional organizations have recognized her achievements as a clinician, researcher, and scholar. -
Robert Lane Smith
Professor (Research) of Orthopedic Surgery, Emeritus
Current Research and Scholarly InterestsOur group is interested in the molecular and cell biology underlying bone and cartilage metabolism in health and disease. Normal daily activities are linked to the ability of the articular cartilage to withstand normal joint forces that may reach 5-7 times body weight and bone homeostasis depends on daily mechanical loading histories.
-
Stephanie Melissa Smith
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsI am involved with clinical research related to cancer survivorship, with a particular focus on late effects of childhood cancer treatments and community partnerships to improve health equity for adolescent/young adult cancer survivors in under-resourced settings.
-
Stephen J Smith
Professor of Molecular and Cellular Physiology, Emeritus
Current Research and Scholarly InterestsStephen Smith remains active in the computational microscopy field and is also currently using data science tools to explore new transcriptomic perspectives on signaling by neuropeptides and other neuromodulators in brains of diverse animal species. These exploration have unearthed evidence for a previous unrecognized ubiquity of local neuropeptide signaling and possible critical involvement of such signaling in memory engram formation.
-
Stephen Smith, MD
Clinical Assistant Professor, Ophthalmology
Current Research and Scholarly InterestsRESEARCH OVERVIEW
Dr. Smith’s primary professional interest is developing solutions for unmet clinical and surgical vitreoretinal needs. Beginning in medical school, one of his primary focuses has been improving treatment outcomes in patients with retinoblastoma (RB). During his second year in medical school Dr. Smith published a manuscript on a novel technique to reduce the risk of tumor spread following intravitreal drug delivery in patients with RB. His work summarizing published data on tumor spread following intravitreal injection therapy (IVT) for RB has resulted in multiple platform presentations at national and international meetings, including an invited lecture at ARVO 2014. The results of this study influenced the growing trend toward broader acceptance of intravitreal chemotherapy in pediatric patients with treatment-resistant retinoblastoma vitreous seeds. A primary active area of research has included studying and publishing on ocular toxicity that results from the use of intravitreal melphalan and other agents for RB. This work, and subsequent publications from leaders in the field, has led to an increased awareness of ocular toxicity caused by injecting chemotherapeutic agents into the eyes of young children. This highlighted the need for toxicity data on additional chemotherapeutic agents for local delivery. To answer this question, Dr. Smith assembled an excellent group of collaborators and consultants, including internationally known experts at Bascom Palmer, Mayo Clinic, and Emory University. As a resident he secured a highly competitive career starter grant from the Knights Templar Foundation and used that funding and the expertise of his collaborators to carry out preclinical ocular toxicity studies of combination intravitreal chemotherapy for RB. His work in RB has led to a broader recognition of the challenges facing patients with RB who receive IVT and has led to a continued search for optimal local injectable therapies for patients with this disease.
INNOVATION HIGHLIGHTS
In addition to his work in retinoblastoma, Dr. Smith has been actively involved in developing technologies to improve outcomes for patients receiving intravitreal injection therapy (IVT) for macular degeneration, diabetic retinopathy, retinal vein occlusions and more. IVT has become the most common procedure performed by retina specialists in the United States, with an estimated 6 million injections given in the United States alone in 2016. Dr. Smith has co-developed technology that simplifies and streamlines the IVT process, removing barriers to treatment and improving patient outcomes. His work in innovation covers pre-clinical and clinical development work, and has given him expertise in diverse subject areas including fundraising, intellectual property portfolio development, team building, and business administration. He is a co-founder of iRenix Medical, a biotechnology and medical device start-up company committed to improving vision through optimization of the IVT process.
Dr. Smith remains dedicated to helping improve and restore vision and quality of life in patients with vitreoretinal disease. He is currently involved in both medical device and pharmaceutical innovation, and serves as a mentor for the Stanford University Biodesign Innovation Course.
